AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$2.48 USD
-0.09 (-3.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $2.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.48 USD
-0.09 (-3.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $2.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 13.33% and 27.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GSK (GSK) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 9% and 4.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for AbCellera Biologics Inc. (ABCL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 18.03% and 20.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -4.76% and 1.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AbCellera Biologics Inc. (ABCL) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -3.77% and 0.27%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for October 26th
by Zacks Equity Research
GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 15.38% and 21.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?
by Zacks Equity Research
Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.
Strength Seen in Pliant Therapeutics, Inc. (PLRX): Can Its 8.3% Jump Turn into More Strength?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
by Zacks Equity Research
AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.
Implied Volatility Surging for AbCellera Biologics (ABCL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AbCellera Biologics (ABCL) stock based on the movements in the options market lately.
AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for AbCellera Biologics Inc. (ABCL) points to a 137.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.